Data from a prospective multisite cohort study were used to examine the effect of HIV exposure, untreated HIV infection, and single-dose nevirapine on infant growth velocity. The 2009 WHO growth velocity standards constitute a new tool for this type of investigation and are in need of functional validation. In period 1 (3-24 wk), 65 HIV-infected, 502 HIV-exposed uninfected (HEU), and 216 HIV-unexposed infants were included. In period 2 (25-36 wk), 31 infants moved from the HEU group to the HIV-infected group. We compared weight velocity Z-scores (WVZ) and length velocity Z-scores (LVZ) by HIV group and assessed their independent influences. In period 1, mean WVZ (95% CI) was 
Introduction
Malnutrition is an underlying cause of one-third of the 6.9 million global child deaths (1, 2) . Prevention and management thereof is thus a public health priority. HIV infection is associated with poor growth and development in utero and postnatally. Longitudinal studies conducted in developing countries show differences in attained Z-scores between HIV-infected and HIV-exposed uninfected (HEU) 8 children from as early as 3-4 mo of age until 24 mo (3, 4) . Prevention of mother-to-child transmission of HIV (PMTCT) programs have made it possible for more HEU infants to remain uninfected (5) . These infants generally display similar growth patterns to unexposed infants (4), although transient differences in growth have been observed in some studies (6) (7) (8) (9) . Suboptimal growth of HEU infants in developing countries could be caused by increased exposure to opportunistic infections, such as tuberculosis, or altered/suboptimal infant feeding and care practices or by parental illness or death (10) (11) (12) (13) . In the domain of HIV/AIDS research, longitudinal growth studies have mostly assessed changes in attained Z-scores (4) . Very few have looked at growth velocity (increments per time period) (14) . Restricting research to changes in attained Z-scores disregards important age differences in growth rates. For example, a 0.5 increase in attained length-for-age Z-scores (LAZ) over the first 6 mo of life is normal, whereas the same Z-score increase between ages 4 and 4.5 y represents fast growth in that age period. In addition to the attained growth standards (15, 16) , the WHO published growth velocity standards that more accurately represent growth rates over a period of time by ensuring that, in each age period, anthropometric scoring is done in reference to the normal growth rate in that specific age period (17) . These growth velocity standards have been used rarely in growth research to date (18) . This paper reports on patterns of growth velocity among HIV-exposed and -unexposed infants between 3 and 36 wk postpartum and on the variables that influence growth velocity.
Materials and Methods
Data are from a prospective observational cohort study (Good Start I Study), primarily assessing HIV vertical transmission and HIV-free survival by 36 wk postpartum in three purposively selected sites: 1) Paarl (peri-urban area); 2) Rietvlei (rural area); and 3) Umlazi (peri-urban township). Details of the study have been published previously (19) . In summary, pregnant women (34-36 wk gestation) were screened for enrollment antenatally or postnatally while still hospitalized. A total of 883 consented mother-infant pairs were recruited from October 2002 to November 2004 and followed up until 36 wk after delivery (19, 20) . The standard of care at the time of the study included single-dose nevirapine to HIV-positive pregnant women at the onset of labor and to their infants within 72 h of delivery, exclusive breastfeeding (EBF) for 3-4 mo, followed by abrupt cessation or avoidance of breastfeeding, free formula milk for non-breastfeeding mothers from delivery to 6 mo after delivery, and cotrimoxazole prophylaxis to HIV-exposed infants from 6 wk after delivery (21) . No antiretroviral treatment was available.
Trained field staff collected interview data on socioeconomic status, infant feeding practices, cotrimoxazole use, and other health-related factors during fortnightly (3-9 wk) and monthly (12-36 wk) home visits. Information on infant feeding included whether the infant received any of 15 items ''yesterday'' (from sunrise yesterday until sunrise today) and for 3 d before ''yesterday.'' Information on infant sickness included 2-wk recall on fast/difficult breathing and diarrhea (more than five loose stools a day). Data on infant birth weight, gestational age (based on fundal height and motherÕs last reported menstrual period), nevirapine use, other antiretroviral (ARV) prophylaxis, and maternal HIV status were extracted from routine PMTCT/perinatal records (19, 20) . Birth length was not extracted because it was seldom documented. Maternal viral load (copies per milliliters) was determined from a maternal blood spot taken from known HIV-positive mothers at 3 and 36 wk postpartum. The average of the 2 log 10 -transformed viral loads was used for analysis. Infant dried blood spot specimens were collected from HIVexposed infants at 3, 24, and 36 wk and tested for infection (HIV-1 DNA PCR assay; Amplicor HIV-1 Monitor, version 1.5; Roche Molecular Systems) (19, 20) .
Field staff measured infant weight and recumbent length at 3, 24, and 36 wk using identical instruments in all sites. Infants were weighted to the nearest 0.1 kg wearing minimum clothing on Masskot (SOS Series) electronic pan scales, calibrated weekly using a 2 kg weight. Recumbent length measurements were obtained to the nearest 0.1 cm using roller meters (TALC) (20). All field workers received standardized training on anthropometric techniques. To improve validity and reduce interobserver and intra-observer bias, the anthropometry data collection was validated periodically. Infant age was calculated using the date of birth from the Road to Health card and the date of the interview.
Data were double-entered into a Microsoft Access database and analyzed using Stata version 12 (StataCorp) and IBM SPSS Statistics version 19 for Windows (SPSS).
Anthropometric scoring. Attained LAZ, weight-for-age Z-scores (WAZ), and weight-for-length Z-scores (WLZ) were computed for each infant using the 2006 WHO growth standards (22) . A macro based on the 2009 WHO growth velocity standards was used to compute the weight velocity Z-scores (WVZ) and length velocity Z-scores (LVZ) [macro obtained from OÕNeill et al. (18) ]. The WHO growth velocity standards provide reference increments for prespecified age intervals. These age intervals did not always exactly correspond with observed intervals in the Good Start study sample. Therefore, velocity Z-scores were calculated by identifying the best-fitting tabulated WHO age interval that closely matched the infant age period observed, as recommended by WHO (17) .
Data cleaning.
Anthropometric measurement values and Z-scores were flagged for verification if any of the following criteria were met: decrease in length of >2 cm between 2 consecutive visits; WAZ less than 26 or >6, WLZ less than 26 or > 6, LAZ less than 26 or >3, WLZ >3 and LAZ less than 23; extreme changes in LAZ between visits defined as LAZ at 3 wk <2 and LAZ at 24 wk >2.5, or LAZ at 24 wk <2 and LAZ at 36 wk >2.5; changes >4 or less than 24 Z-scores between 24 and 36 wk . All flagged anthropometric observations were assessed, and values were treated as missing if no plausible explanation was determined, e.g., catch-up growth of premature infants. In total, 19 infants were excluded from the analysis. An additional 81 infants were excluded because of inconclusive HIV test results.
Statistical analyses. Infants were categorized as HIV-infected infants (infected) if they tested positive to an HIV-1 PCR test, HIV-negative infants born to HIV-positive mothers (HEU), or HIV-negative infants born to HIV-negative mothers (unexposed). To avoid reverse causality, we used the 3-and 24-wk infant HIV test to classify infants into HIV groups during period 1 and period 2: infants HIV positive at 3 wk were defined as infected in period 1 (3-24 wk) , and infants who newly tested HIV positive at 24 wk were considered HEU in period 1 and infected in period 2 (24-36 wk).
Infants were categorized into the following four feeding groups at 5 wk to determine the effect of early feeding on growth: 1) EBF, defined as breast milk only (no other fluids or semisolid/solid foods) with or without prescribed medicines; 2) exclusive formula feeding, defined as commercial infant formula milk only without any breast milk; 3) mixed breastfeeding, defined as breast milk with nutritive liquids or solids; or 4) mixed formula feeding (MFF), defined as commercial infant formula milk with other nutritive liquids and solids, without breast milk (23) .
We used one-factor ANOVA to compare mean Z-scores between the three HIV groups, risk ratios to assess strengths of associations, paired t tests to compare mean differences in velocity Z-scores, and PearsonÕs x 2 test (or FisherÕs exact test if a cell had less than five observations) to examine associations in the cross-tabulations.
In a descriptive analysis, we explored factors independently associated with WVZ and LVZ. Mixed-effects regression models, with an unstructured variance-covariance matrix, were used for this analysis of velocity Z-scores. The following variables were included as independent variables because of their epidemiologic or clinical importance: group, period, site (as a proxy for socioeconomic status), maternal age, gender, infant feeding practice, infant sickness between birth and 3 wk, birth weight, and gestational age. A group 3 period interaction term was also included in the multivariate models because we expected that growth between the groups would differ in the 2 periods. Additional stratified analysis was conducted to understand the nature of the interactions. Maternal viral load (log transformed), cotrimoxazole, and nevirapine infant prophylaxis were taken into account in the models that only considered HIV-exposed infants. Variables were included in the multivariate models based on results from bivariate analyses. WVZ, LVZ, and log 10 viral load were used in the continuous form. Values in the text are means 6 SDs unless otherwise stated. Statistical tests were 2-sided and performed at the 5% significance level.
Ethical approval. Ethical approval was obtained from the University of the Western Cape and the University of KwaZulu-Natal.
Results
Participant characteristics. The total number of mother-infant pairs considered in the analysis was 783, comprising 65 infected, 502 HEU, and 216 unexposed infants in period 1. Thirty-one additional infants became infected by the 24-wk visit, increasing the total number of HIV-infected infants to 96 and reducing the HEU to 471 in period 2. The three groups did not differ by maternal factors (education, age, parity, and site) and infant gender. The mean birth weight of infected infants (2820 6 516.12 g) was lower (P < 0.001) than that of HEU (3071 6 519.17 g) and unexposed (3086 6 528.94 g) infants ( Table 1) . At 3 wk, the mean WAZ of infected infants was 21.30 6 1.65 and was lower than that of HEU (20.60 6 1.34) and unexposed (20.51 6 1.25) infants (P < 0.001). The mean WAZ, LAZ, and WLZ of infected infants were lower than those of HEU and unexposed infants at 24 and 36 wk. No differences in mean WAZ, LAZ, and WLZ were observed between the HEU and unexposed infants at any time point (Table 1) .
Growth velocities in period 1 (3-24 wk) and period 2 (25-36 wk). Overall, WVZ ranged from 28.01 to 6.06 in period 1 and from 210.06 to 5.14 in period 2. LVZ ranged from 27.66 to 7.61 in period 1 and from 26.62 to 8.6 in period 2.
Mean WVZ differed (P < 0.001) between the groups in the first period but not in the second ( Table 2) . Infected infants had a lower mean WVZ compared with HEU infants (P < 0.001) and unexposed infants (P < 0.001). Sickness episodes were most frequent among the infected infants (40%), and these infants had 1.77 (1.32, 2.37) times the risk of being sick at 3 wk compared with unexposed infants. The mean WVZ of HEU infants tended to be higher than that of unexposed infants (P = 0.06).
Mean LVZ differed (P = 0.005) between the groups in period 1 but not in period 2 ( Table 2) . Infected infants had a lower mean LVZ compared with HEU infants (P = 0.002) and unexposed infants (P = 0.033). The mean LVZ of HEU infants was not significantly higher than that of unexposed infants. High LVZ ($2) was more frequent in low-birth-weight infants (42%) than in infants with normal birth weight (18%) in period 1 (P < 0.001).
Factors associated with WVZs in mixed-effect models. Infants in Umlazi had a 0.43 higher mean WVZ compared with infants in Paarl (P = 0.002). Mixed breastfeeding was observed in 48 and 29% of infants in Umlazi and Paarl, respectively, at 5 wk (P < 0.001). Infants that were MFF had a 0.41 (0.08, 0.74) higher mean WVZ compared with EBF infants (P = 0.015).
Mean WVZ was significantly associated with group, period, and maternal viral load in model 2. Differential WVZs were Factors associated with LVZs in mixed-effect models. EBF, exclusive breastfeeding; EFF, exclusive formula feeding; HEU, HIV-exposed uninfected; MBF, mixed breastfeeding; MFF, mixed formula feeding; WVZ, weight velocity Z-score. 2 Model 1 included 783 HIV-exposed and -unexposed infants with 1566 observations. 3 Model 2 included 567 HIV-exposed infants with 1134 observations. 
Discussion
The effect of HIV exposure, infection, and nevirapine prophylaxis on infant growth velocity requires additional investigation. The 2009 WHO growth velocity standards constitute a new tool for this type of investigation and are in need of functional validation (17) . Velocity Z-scores have some characteristics that differentiate them from attained Z-scores. Unlike attained Z-scores, extreme velocity Z-score values beyond 24 or +4 can temporarily occur in children with growth and nutrition problems or during periods of catch-up, and return to the normal 22 to +2 range in a subsequent period. Period-to-period variability in velocity Z-scores is high, even in normally growing children, such as those in the WHO sample (17) . Using the WHO velocity standards, we studied growth patterns in a prospective study of HIV-exposed and -unexposed infants that took place in the early years of the South African PMTCT program when only singledose nevirapine ARV prophylaxis was available. To our knowledge, here we provide the first report on growth velocity among HIV-exposed and -unexposed infants using the 2009 WHO growth velocity standards. We demonstrate that HIV infection in infants is not only associated with lower birth weights but is also related to poorer WVZ and LVZ in the first 6 mo of life in the absence of ARV treatment. Olusanya and Renner (14) also reported lower mean weight velocity (grams per kilograms per day) in their sample of HIV-exposed infants compared with the unexposed infants. Although infant HIV status was unknown in the study, the authors speculate that a large proportion of the HIV-exposed infants may have been infected. Lower mean WAZ, WLZ, and LAZ were also observed in infected infants in the first 6 mo in our sample, confirming findings from other studies in sub-Saharan Africa (4). This confirms that HIV-infected infants are born with lower birth weights and are susceptible to experience a wasting and stunting process attributable to either HIV disease or intercurrent morbidity. Our findings show poorer weight velocity in the first 6 mo among infants that had been sick compared with their healthy counterparts. Acute illnesses were more prevalent among the HIVinfected infants, and these infants had a greater risk of being sick compared with the other 2 groups. This strongly suggests that opportunistic infections were associated with the poorer growth patterns of these HIV-infected children (24) . Our results also show that maternal viral load is inversely associated with WVZ in exposed infants. Maternal viral load is a risk factor for mother-tochild transmission of HIV (5), and poor infant weight gain has been reported previously with higher maternal viral loads (25) . Therefore, HIV-exposed infants with poor growth velocities and an unknown or previously negative HIV test result should be referred for HIV testing and counseling and additional care as needed. Great gains have been made in scaling up HIV prevention and treatment interventions since the time of the study. The primary prevention of HIV infection among women of reproductive age and the treatment of pregnant women living with HIV have been identified as essential interventions for the reduction of mother-to-child transmission of HIV to reach the global target of zero new infections by 2015 (26) . Single-dose nevirapine prophylaxis given to both the HIV positive women and their babies was associated with higher LVZ in our study, highlighting the importance of strengthening PMTCT service delivery. MFF infants had a greater mean WVZ compared with EBF infants, possibly because of the higher energy and protein per kilogram body weight in formula-fed than in breastfed infants. Commercial infant formulas also have higher average caloric density (kcal/100 mL) compared with breast milk. There are no known adverse consequences associated with the slower weight gain in breastfed infants (27, 28) . Instead, rapid weight gain in formula-fed infants may be a risk factor for later insulin resistance, obesity, and cardiovascular disease (29) .
Higher LVZ was associated with low birth weight, and this is indicative of catch-up growth (30) (31) (32) . We also compared the patterns of growth velocities between 2 successive periods and demonstrated that a low LVZ in the first 6 mo of life is associated with a high LVZ in subsequent months.
As to strengths and limitations, first, we did not measure maternal weight and height, so maternal BMI could not be calculated. Second, no HIV testing was performed on the mothers during the study. It is possible that some HIV-negative mothers may have sero-converted after delivery, leading to misclassification of their infants as unexposed. Although blood specimens were collected to estimate viral loads, they were only collected twice during the 3-and 36-wk visit times. Our results are also subject to recall bias on contrimoxazole and infant feeding practices. Some infants had incomplete growth velocity because of missing weight or length values or because their data were excluded during the data cleaning process. Therefore, a decision was made to use mixed-effect models to assess the longitudinal relation between velocity Z-scores and independent variables as they adjust for missing data. These models use all available longitudinal data, i.e., without summarizing measurements of each group into a single value, such as the mean of the repeated measurements or a single measurement at the end of the follow-up period (33) . Mixed-effect models also adjust for the correlation between measurements taken from the same group by allowing regression coefficients to vary between groups (33). The maximum likelihood estimation function within these models enables them to cope better with missing data (34), making them appropriate for the current study because not all the participants had complete anthropometric data. To avoid reverse causality, we only considered the infants that were HIV positive at 3 wk (i.e., at the beginning of period 1) as infected in period 1. Infants that tested HIV positive at 24 wk were considered uninfected in period 1. The same strategy was used to classify infants in period 2 so that HIV infection (the exposure) preceded the period when the growth was assessed. In addition, reverse causality is unlikely in our analysis because 1) higher maternal viral load was significantly associated with lower mean velocity Z-scores, which further supports the notion that HIV infection results in poor growth, and 2) HEU infants showed similar growth patterns to unexposed infants.
In conclusion, HIV infection, and not exposure, was associated with low WVZ and LVZ. High WVZ was associated with MFF, whereas low WVZ was associated with infant sickness and high maternal viral loads. LVZ had an inverse relation with birth weight, and HIV-exposed infants that had received nevirapine had higher LVZ. Higher WVZ and LVZ were associated with early introduction of solids. Eliminating infant HIV infection is a critical component in averting HIV-related poor growth patterns in infants in the first 6 mo of life.
